Literature DB >> 11869690

CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor.

Rebecca S McHugh1, Matthew J Whitters, Ciriaco A Piccirillo, Deborah A Young, Ethan M Shevach, Mary Collins, Michael C Byrne.   

Abstract

CD4(+)CD25(+) immunoregulatory T cells represent a unique lineage of thymic-derived cells that potently suppress both in vitro and in vivo effector T cell function. We analyzed CD4(+)CD25(+) and CD4(+)CD25(-) T cells by DNA microarray, identifying 29 genes differentially expressed in the resting subpopulations, and 77 that were differentially expressed following activation. Most of these genes were elevated in the CD4(+)CD25(+) population, suggesting a previously activated phenotype. Among these were a number of genes that antagonize signaling, including members of the SOCS family, which may contribute to their anergic phenotype. Multiple cell surface receptors also had increased expression in CD4(+)CD25(+) cells, including GITR, a member of the TNF receptor superfamily. Importantly, antibodies to GITR abrogated suppression, demonstrating a functional role for this receptor in regulating the CD4(+)CD25(+) T cell subset.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11869690     DOI: 10.1016/s1074-7613(02)00280-7

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  405 in total

Review 1.  Resolving the identity myth: key markers of functional CD4+FoxP3+ regulatory T cells.

Authors:  Xin Chen; Joost J Oppenheim
Journal:  Int Immunopharmacol       Date:  2011-05-31       Impact factor: 4.932

2.  Costimulatory signals controlling regulatory T cells.

Authors:  Joerg Ermann; C Garrison Fathman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-15       Impact factor: 11.205

3.  CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism.

Authors:  Zhenhua Dai; Qi Li; Yinong Wang; Ge Gao; Lonnette S Diggs; George Tellides; Fadi G Lakkis
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

4.  Suppressor T cells, rebranded as regulatory T cells, emerge from the wilderness bearing surface markers.

Authors:  T T MacDonald
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

Review 5.  Advances in the development of cancer immunotherapies.

Authors:  Jianjun Gao; Chantale Bernatchez; Padmanee Sharma; Laszlo G Radvanyi; Patrick Hwu
Journal:  Trends Immunol       Date:  2012-09-30       Impact factor: 16.687

6.  The CD137 Ligand Is Important for Type 1 Diabetes Development but Dispensable for the Homeostasis of Disease-Suppressive CD137+ FOXP3+ Regulatory CD4 T Cells.

Authors:  Bardees M Foda; Ashley E Ciecko; David V Serreze; William M Ridgway; Aron M Geurts; Yi-Guang Chen
Journal:  J Immunol       Date:  2020-04-15       Impact factor: 5.422

Review 7.  TNF superfamily: costimulation and clinical applications.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Cell Biol Int       Date:  2009-02-20       Impact factor: 3.612

8.  Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.

Authors:  Madhav D Sharma; Babak Baban; Phillip Chandler; De-Yan Hou; Nagendra Singh; Hideo Yagita; Miyuki Azuma; Bruce R Blazar; Andrew L Mellor; David H Munn
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

9.  BRG1-mediated immune tolerance: facilitation of Treg activation and partial independence of chromatin remodelling.

Authors:  Barbara H Chaiyachati; Anant Jani; Yisong Wan; Haichang Huang; Richard Flavell; Tian Chi
Journal:  EMBO J       Date:  2013-01-15       Impact factor: 11.598

10.  Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.

Authors:  Adam D Cohen; Adi Diab; Miguel-Angel Perales; Jedd D Wolchok; Gabrielle Rizzuto; Taha Merghoub; Deonka Huggins; Cailian Liu; Mary Jo Turk; Nicholas P Restifo; Shimon Sakaguchi; Alan N Houghton
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.